0.4826 USD
-0.2335
32.61%
At close Dec 20, 4:00 PM EST
After hours
0.4829
+0.0003
0.06%
1 day
-32.61%
5 days
-22.16%
1 month
-36.01%
3 months
-49.48%
6 months
-74.73%
Year to date
-83.36%
1 year
-82.19%
5 years
-99.88%
10 years
-100.00%
 

About: Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing, and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and Pantheris, an image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States.

Employees: 76

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

1.78% more ownership

Funds ownership: 4.33% [Q2] → 6.11% (+1.78%) [Q3]

0% more funds holding

Funds holding: 12 [Q2] → 12 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

18% less capital invested

Capital invested by funds: $164K [Q2] → $134K (-$29.9K) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for AVGR.

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript
Avinger, Inc. (NASDAQ:AVGR ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Investor Relations Jeffrey Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and welcome to the Avinger Third Quarter 2024 Results Conference Call.
Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Avinger (AVGR) Reports Q3 Loss, Tops Revenue Estimates
Avinger (AVGR) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.03. This compares to loss of $2.92 per share a year ago.
Avinger (AVGR) Reports Q3 Loss, Tops Revenue Estimates
Neutral
Accesswire
1 month ago
Avinger Reports Third Quarter 2024 Results
Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024. Third Quarter and Recent Highlights Reported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.
Avinger Reports Third Quarter 2024 Results
Neutral
Accesswire
1 month ago
Avinger to Announce Third Quarter 2024 Results on November 7, 2024
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Avinger to Announce Third Quarter 2024 Results on November 7, 2024
Neutral
Accesswire
1 month ago
Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention
REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.
Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention
Neutral
Accesswire
3 months ago
Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents
REDWOOD CITY, CA / ACCESSWIRE / September 18, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of a new U.S. patent and the allowance of five additional U.S. patents that are expected to issue over the next four months. These patents expand intellectual property protection for Avinger's proprietary image-guided system and devices for both peripheral and coronary applications.
Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents
Positive
Zacks Investment Research
4 months ago
Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment
Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.
Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment
Neutral
Accesswire
4 months ago
Avinger Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device
REDWOOD CITY, CA / ACCESSWIRE / August 20, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of the Pantheris LV image-guided directional atherectomy system. With the initiation of full commercial launch, all current and prospective accounts can now order the Pantheris LV device, a line extension of the first and only image-guided atherectomy device for the treatment of peripheral artery disease (PAD).
Avinger Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device
Neutral
Seeking Alpha
4 months ago
Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript
Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript
Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 months ago
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
Avinger (AVGR) came out with a quarterly loss of $2.82 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $8.85 per share a year ago.
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
Charts implemented using Lightweight Charts™